Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ: MNMD )

6.230 -0.200 (-3.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
U.S. Is Dominating Psychedelic Drugs Market Due To Growing Acceptance For Treating Depression & Rise In Product Approvals
Palm Beach, FL –October 12, 2021 – FinancialNewsMedia.com News Commentary – After being relegated to the margins of sincere scientific examination for about the last several decades, growing... 
Via FinancialNewsMedia
Psyched: Seattle Decriminalizes Psychedelics, Psilocybin Increases Emotions From Music, Novamind's Palliative Care Program
The Week In Psychedelics 
Via Benzinga
Former Tilray CEO Joins Psychedelics Company
More big names in cannabis are switching to psychedelics. Greg Engel, former CEO of Tilray (NASDAQ: 
Via Benzinga
Topics Cannabis
Exposures Cannabis
MindMed Teams Up With Sphere Health To Identify Biomarkers Associated With Anxiety & Depression
Psychedelic–focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) disclosed on Tuesday that it has agreed to partner with Sphere Health to... 
Via Benzinga
Cannabis Movers & Shakers: Leafly Holdings, Linneo Health, Flowhub, MindMed
Leafly Holdings Taps Suresh Krishnaswamy As New CFO The cannabis information platform Leafly Holdings, Inc. recently disclosed ... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Psychedelic Front Runners MindMed , BioXcel Patent System To Identify Agitation
This article by Gaurav Dubey was originally published on 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
COVID Tests, THC Patches, Psychedelics: Xphyto Therapeutics Does it All
Image by Shameer Pk from Pixabay From 25-minute COVID-19 lab tests to psychedelic medicine that is poised to address mental health conditions like PTSD, XPhyto Therapeutics (... 
Via Benzinga
Exposures COVID-19
6 Psychedelic Stocks With Buy Rating: Why Are They Good Investments?
This article by Jason Najum was originally published on 
Via Benzinga
NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Therapeutic Options to Diseases with Unmet Needs
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
Four Stocks Disrupting Mental Health To Keep An Eye On At Benzinga's Healthcare Conference
The healthcare sector is booming and startups are the driving force behind the innovations that will affect the future of life on earth. ... 
Via Benzinga
Digital Therapeutics And The Future Of Psychedelic Medicine
Digital health and therapeutics will play a crucial role in the future of medicine. Across medical and mental health industries, companies are real... 
Via Benzinga
Psychedelics Renaissance Underway as Paradigm Shifting Cure for Depression Potentially Discovered
Via FinancialNewsMedia
Topics Law Enforcement
Exposures Legal
Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study
The Week In Psychedelics: 
Via Benzinga
Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
Senate Bill Decriminalizing Psychedelics Could Help Reverse Some “War on Drugs” Impacts
Via FinancialNewsMedia
Which Psychedelic Stock ETF Is Right For You?
This week the AdvisorShares Psychedelics ETF began trading on the NYSE Arca. Here we compare the make-up of the now 3 psychedelic stock ETFs and two tracking indexes. 
Via Talk Markets
Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0
Psychedelics biotech company Compass Pathways (NASDAQ:CMPS... 
Via Benzinga
Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry?
By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate... 
Via Benzinga
National Suicide Prevention Week Shines Light on Psychedelic Treatments
Via FinancialNewsMedia
Psyched: Field Trip Gets $20 Price Target, DEA Seeks To Increase Psilocybin Production Limits, Synthesis Closes $7.25M Series A
Contents 
Via Benzinga
Psychedelic Drug Industry Report Card For 2021
In assessing the psychedelic drug industry, a primary focus for investors is drug development. 
Via Talk Markets
EXCLUSIVE: Kevin O'Leary Unpacks Deal Flow, Investments, Perspectives On Disruptive Innovation
A lot has changed since Benzinga last spoke with Kevin O’Leary, businessman, author, "Shark Tank's" Mr... 
Via Benzinga
Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold
Contents 
Via Benzinga
Magic Mushroom Drug Stock Performances YTD
Of the 35 companies involved in clinical stage research of psychedelic substances, 20 are researching the benefits of psilocybin, the primary psychoactive ingredient in “magic mushrooms”. 
Via Talk Markets
MindMed Teams Up With Forian To Improve Real-World Evidence Data To Help Psychiatric Patients
Psychedelics-focused medicines company Mind Medicine Inc. (NASDAQ: 
Via Benzinga
Cramer Weighs In On RealReal, Affirm Holdings And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said no to RealReal Inc (NASDAQ: REAL). He is not a buyer because there are too many of these guys. Mind Medicine (... 
Via Benzinga
Push the Boundaries of DMT Therapy with Mind Medicine
Ready to explore an under-developed area of psychedelic medicine? If so, then consider a long position in low-priced MNMD stock. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
MindMed Reports Q2 Earnings With Net Loss of $36M And Cash Balance Of $157M To Continue With Its Clinical Pipeline
The psychedelics-focused medicines company MindMed (NASDAQ: 
Via Benzinga
No Matter How the Pandemic Rolls, Mind Medicine Will Prevail
While MNMD stock is controversial due to its underlying psychedelic therapies, the broader narrative is exceptionally compelling. 
Via InvestorPlace
Which Psychedelic Drug Has The Most Commercial Potential?
As the Mental Health Crisis has become a mental health pandemic, clinical research on psychedelic drugs is showing that these substances are the best – and only – option to address this crisis. 
Via Talk Markets
< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.